New York, New York (PRWEB) August 13, 2013
Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) involving allegations that the drug caused users to suffer life-threatening episodes of internal bleeding continue to move forward in a multidistrict litigation now underway in U.S. District Court, Southern District of West Virginia, Bernstein Liebhard LLP reports. According to a Case Management Order dated August 9th, the Court has established some limitations that address certain ex parte communications. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
“Our Firm continues to hear from individuals who have allegedly suffered severe internal bleeding, a potentially life-threatening Pradaxa side effect. We are pleased to see this litigation moving forward, and are looking forward to the commencement of bellwether trials next year,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to alleged victims of Pradaxa bleeding.
Court documents indicate that more than 1,390 Pradaxa lawsuits are currently pending in the multidistrict litigation underway in the Southern District of Illinois, all of which allege that Boehringer Ingelheim failed to provide adequate warnings regarding Pradaxa side effects, particularly the lack of an antidote for internal bleeding. The first bellwether trial in the Pradaxa bleeding litigation is scheduled to start in September 2014.
Pradaxa was approved for sale by the U.S. Food & Drug Administration (FDA) in October 2012 to prevent strokes in people with a heart-rhythm disorder known as atrial fibrillation. According to a recent Bloomberg.com report, the drug was positioned as an improvement over warfarin, a blood thinner that has been on the market for decades. While both drugs are known to sometimes cause serious incidents of internal bleeding, there is no readily available antidote for Pradaxa bleeding. However, similar hemorrhaging that may occur in warfarin patients can be stopped via the administration of vitamin K.* In January, an analysis appearing in the QuarterWatch Report from the Institute for Safe Medicine Practices (ISMP) found that Pradaxa bleeding is 5 times more likely to result in death compared to warfarin bleeding. The authors of that analysis surmised that the lack of an antidote for Pradaxa patients may contribute to the higher death rate associated with the drug.
Individuals who have suffered serious episodes of internal bleeding while taking Pradaxa may be entitled to compensation for their medical bills, lost wages, pain and suffering and more. Learn More about Pradaxa bleeding at Bernstein Liebhard LLP’s website. To arrange for a free legal consultation, please call 800-511-5092.
*bloomberg.com/news/2012-12-11/boehringer-sued-by-hundreds-over-bleeding-tied-to-pradaxa.html, Bloomberg.com, December 11, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
Read the full story at http://www.prweb.com/releases/pradaxa-lawsuit/pradaxa-bleeding/prweb11022986.htm.
Copyright©2012 Vocus, Inc.
All rights reserved